Drugs / CoVaccine HT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01015703 | Nov 2009 → Jun 2010 | — | BTG International Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00895466 Background | Oct 2008 → Dec 2009 | prostate cancer | Pepscan Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00702221 Background | Jun 2008 → Jun 2009 | hypertensive disorder | BTG International Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoVaccine HT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00702221 ↗ |
| Route | Intramuscular | “Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart” NCT00702221 ↗ |